Listed

Amphastar Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2014

Filed with the SEC on Mar 26, 2015 and accepted by EDGAR at Mar 26, 2015, 06:10 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-10-01 to 2014-12-31$55.9mus-gaap:SalesRevenueNet
Revenue12 months2014-01-01 to 2014-12-31$210.5mus-gaap:SalesRevenueNet
Cost of revenue12 months2014-01-01 to 2014-12-31$159.2mus-gaap:CostOfRevenue
Gross profit3 months2014-10-01 to 2014-12-31$12.0mus-gaap:GrossProfit
Gross profit12 months2014-01-01 to 2014-12-31$51.3mus-gaap:GrossProfit
Research and development12 months2014-01-01 to 2014-12-31$28.4mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2014-01-01 to 2014-12-31−$18.0mus-gaap:OperatingIncomeLoss
Interest expense12 months2014-01-01 to 2014-12-31$609.0kus-gaap:InterestExpense
Income tax12 months2014-01-01 to 2014-12-31−$7.4mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2014-10-01 to 2014-12-31−$2.5mus-gaap:NetIncomeLoss
Net income12 months2014-01-01 to 2014-12-31−$10.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2014-10-01 to 2014-12-31−$0.06us-gaap:EarningsPerShareDiluted
Diluted EPS12 months2014-01-01 to 2014-12-31−$0.25us-gaap:EarningsPerShareDiluted
Basic EPS3 months2014-10-01 to 2014-12-31−$0.06us-gaap:EarningsPerShareBasic
Basic EPS12 months2014-01-01 to 2014-12-31−$0.25us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2014-10-01 to 2014-12-3144,648,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)12 months2014-01-01 to 2014-12-3141,957,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2014-01-01 to 2014-12-31$21.1mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure12 months2014-01-01 to 2014-12-31$18.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases12 months2014-01-01 to 2014-12-31$389.0kus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2014-12-31$67.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-12-31$198.0mus-gaap:AssetsCurrent
Total assetsAt period end2014-12-31$389.4mus-gaap:Assets
Current liabilitiesAt period end2014-12-31$62.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2014-12-31$107.5mus-gaap:Liabilities
Long-term debtAt period end2014-12-31$42.7mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2014-12-31$281.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-15-001654. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.